BenevolentAI Revenue and Competitors
Estimated Revenue & Valuation
- BenevolentAI's estimated annual revenue is currently $87.9M per year.
- BenevolentAI received $115.0M in venture funding in April 2018.
- BenevolentAI's estimated revenue per employee is $217,000
- BenevolentAI's total funding is $292M.
- BenevolentAI's current valuation is $1B.
Employee Data
- BenevolentAI has 405 Employees.
- BenevolentAI grew their employee count by 25% last year.
BenevolentAI Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $2M | 20 | N/A | N/A | N/A |
What Is BenevolentAI?
BenevolentAI is the global leader in the development and application of artificial intelligence (AI) for scientific innovation. We aim to accelerate the journey from inventive ideas to medicines for patients by developing AI to generate new treatments for some of the world's 8,000 untreated diseases. Our team of technologists, AI researchers, and scientists builds and applies AI to the entire drug discovery and development process. The technology unlocks what is not known by creating new ideas based on established facts to provide a different understanding of disease, which leads to inventive steps and real insights that drive the development of new medicines and treatments. The goal To get the right treatments to the right patients at the right time *Reach out to us* Email: hello@benevolent.ai Careers: Careers@benevolent.ai Twitter: @benevolent_ai Website: benevolent.ai
keywords:Biotechnology, Healthcare, Artificial Intelligence, Technology
$292M
Total Funding
405
Number of Employees
$87.9M
Revenue (est)
25%
Employee Growth %
$1B
Valuation
N/A
Accelerator
BenevolentAI's People
| Name | Title | Email/Phone |
|---|---|---|
1 | VP Platform Architecture | Reveal Email/Phone |
2 | Advanced Software Engineer | Reveal Email/Phone |
3 | Senior Software Engineer | Reveal Email/Phone |
4 | Senior Data Scientist and Manager | Reveal Email/Phone |
5 | VP Discovery Technology | Reveal Email/Phone |
6 | Lead People Partner | Reveal Email/Phone |
7 | Software Engineer | Reveal Email/Phone |
8 | Principal Scientist, Medicinal Chemistry | Reveal Email/Phone |
9 | General Counsel & Company Secretary | Reveal Email/Phone |
10 | VP, Drug Discovery | Reveal Email/Phone |
BenevolentAI News
LONDON, April 25, 2022 /PRNewswire/ -- BenevolentAI (Euronext Amsterdam: BAI), a leading, clinical-stage AI-enabled drug discovery company,...
BenevolentAI is a leading, clinical-stage AI-enabled drug discovery company headquartered in London, with a research facility in Cambridge (UK)...
LONDON, April 21, 2022 /PRNewswire/ -- BenevolentAI, a leading clinical-stage artificial intelligence (AI) enabled drug discovery company, today...
Alec G., Tech Times 17 April 2020, 12:04 pm A.I. might have found the potential cure for COVID-19, and it is already being tested in clinical trials. (Photo : www.pexels.com) Read More: Apple Online Store Down Amidst Preorders of New iPhone SE The Tell of The Tale BenevolentAI, a London star ...
BenevolentAI, a UK artificial intelligence (AI) company focused on health and drug development, has announced a new collaboration, with ...
Other Companies in London
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $146.8M | 405 | 24% | N/A |
#2 | $136.7M | 405 | 18% | N/A |
#3 | $73.4M | 405 | 10% | N/A |
#4 | $62.8M | 405 | 25% | N/A |
#5 | $76.1M | 406 | -4% | N/A |
BenevolentAI Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2018-04-19 | $115.0M | Undisclosed | Article |
BenevolentAI Executives
| Name | Title |
|---|---|
| Jackie Hunter | CEO |
| Joanna Shields | Group CEO |
| Michelle Mahar | Executive Assistant to the President and Vice President of Proximagen and CEO of Pairnomix |
| Rob Quinn | Chief Financial Officer |
| Laura Taddei | Chief Of Staff |
| Davy Suvee | VP Product Management |
| Dewet Diener | VP Engineering |
| Ivan Griffin | VP Business Development |
| James Chandler | VP Corporate Affairs |
| Michelle Mahar | Executive Assistant to the President and Vice President of Proximagen and CEO of Pairnomix |
| Constantinos Neophytou | VP of Engineering |
| Bryn Williams-Jones | SVP Drug Discovery |
| Ed Savory | VP Drug Discovery (Chemical Sciences) |
| Peter Richardson | VP Pharmacology |
| Jane McGuffog | VP Drug Discovery DMPK |